Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2003

01.03.2003 | Original Article

99mTc-interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease

verfasst von: Alessio Annovazzi, Livia Biancone, Renato Caviglia, Marco Chianelli, Gabriela Capriotti, Stephen J. Mather, Renzo Caprilli, Francesco Pallone, Francesco Scopinaro, Alberto Signore

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

Crohn's disease (CD) is a chronic inflammatory bowel disease that may involve the whole gut. Marked intestinal T cell and macrophage activation is a key feature of the disease. Polymorphonuclear cell infiltration is also observed in the diseased gut, mainly during active inflammation. Scintigraphic detection of granulocytes and activated lymphocytes infiltrating the gut wall may be useful in identifying a subgroup of patients with clinically inactive CD who are undergoing early clinical relapse. The aims of the present study were (a) to compare the effectiveness of scintigraphy with 99mTc-labelled interleukin-2 (99mTc-IL2) and with 99mTc-HMPAO labelled granulocytes (99mTc-WBC) in detecting the presence and extent of bowel inflammation in patients with long-term inactive CD (>12 months) and (b) to assess the accuracy of these techniques in predicting future disease relapse. We studied 29 patients with ileal and/or colonic CD in stable clinical remission (Crohn's Disease Activity Index <150 for at least 12 months) using both 99mTc-IL2 and 99mTc-WBC scintigraphy in order to evaluate the extent of acute and chronic inflammation in the bowel. Planar and single-photon emission tomography images were acquired in each patient at 1 h p.i. For quantitative analysis of 99mTc-IL2 uptake, the abdomen was divided into 32 regions of interest. Despite the absence of symptoms, 18 patients (62%) showed a positive 99mTc-IL2 and 18 (62%) a positive 99mTc-WBC scan. Only 12 patients (41.4% of the total group) were positive on both scans, and the sites of IL2 and granulocyte bowel uptake were usually located in different segments, indicating that in CD, acute and chronic inflammation can be present in different sites. As far as the prognostic role of the two scans in predicting future disease relapse is concerned, both 99mTc-IL2 and 99mTc-WBC scintigraphy showed a high negative predictive value (1.00 and 0.91, respectively) but a weak positive predictive value (0.44 and 0.39, respectively). Nevertheless, Kaplan-Meier curves generated between scintigraphic findings and time free from disease relapse were statistically different only for 99mTc-IL2 scintigraphy (log-rank test, P=0.013). These results indicate that 99mTc-IL2 scintigraphy can be useful in selecting CD patients in clinical remission who could benefit from preventive therapy to avoid disease relapse.
Literatur
1.
Zurück zum Zitat Cottone M, Martorana G, Di Mitri R, Camma C, Caprilli R. Epidemiology of inflammatory bowel disease in Italy. Ital J Gastroenterol Hepatol 1999; 31:503–507.PubMed Cottone M, Martorana G, Di Mitri R, Camma C, Caprilli R. Epidemiology of inflammatory bowel disease in Italy. Ital J Gastroenterol Hepatol 1999; 31:503–507.PubMed
2.
Zurück zum Zitat Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:182–205.PubMed Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:182–205.PubMed
3.
Zurück zum Zitat Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, Boirivant M. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease: in vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 1987; 28:745–753.PubMed Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, Boirivant M. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease: in vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 1987; 28:745–753.PubMed
4.
Zurück zum Zitat Choy MY, Walker-Smith JA, Williams CB, McDonald TT. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut 1990; 31:1365–1370.PubMed Choy MY, Walker-Smith JA, Williams CB, McDonald TT. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut 1990; 31:1365–1370.PubMed
5.
Zurück zum Zitat Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, Pallone F. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997; 112:1169–1178.PubMed Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, Pallone F. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997; 112:1169–1178.PubMed
6.
Zurück zum Zitat Monteleone G, Trapasso F, Parrello T, Biancone L, Stella A, Iuliano R, Luzza F, Fusco A, Pallone F. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999; 163:143–147.PubMed Monteleone G, Trapasso F, Parrello T, Biancone L, Stella A, Iuliano R, Luzza F, Fusco A, Pallone F. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999; 163:143–147.PubMed
7.
Zurück zum Zitat Pallone F, Borivant M, Stazi MA, Cosentino R, Prantera C, Torsoli A. Analysis of clinical course of postoperative recurrence in Crohn's disease of distal ileum. Dig Dis Sci 1992; 37:215-219.PubMed Pallone F, Borivant M, Stazi MA, Cosentino R, Prantera C, Torsoli A. Analysis of clinical course of postoperative recurrence in Crohn's disease of distal ileum. Dig Dis Sci 1992; 37:215-219.PubMed
8.
Zurück zum Zitat Biancone L, De Nigris F, Del Vecchio Blanco G, Monteleone I, Vavassori P, Geremia A, Pallone F. Review article: monitoring the activity of Crohn's disease. Aliment Pharmacol Ther 2002; 16 (Suppl 4):29–33. Biancone L, De Nigris F, Del Vecchio Blanco G, Monteleone I, Vavassori P, Geremia A, Pallone F. Review article: monitoring the activity of Crohn's disease. Aliment Pharmacol Ther 2002; 16 (Suppl 4):29–33.
9.
Zurück zum Zitat Best WR, Becktel LM, Singleton JW, Kern F. Development of a Crohn's Disease Activity Index. Gastroenterology 1976; 70:439–444. Best WR, Becktel LM, Singleton JW, Kern F. Development of a Crohn's Disease Activity Index. Gastroenterology 1976; 70:439–444.
10.
Zurück zum Zitat Louis E, Belaiche J, Van Kemseke C, Schaaf N, Mahieu P, Mary JY. Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse. Dig Dis Sci 1995; 40:1750–1756.PubMed Louis E, Belaiche J, Van Kemseke C, Schaaf N, Mahieu P, Mary JY. Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse. Dig Dis Sci 1995; 40:1750–1756.PubMed
11.
Zurück zum Zitat Reinisch W, Gasche C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, Dejaco C, Waldhor T, Bakos S, Vogelsang H, Gangl A, Lochs H. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999; 94:2156–2164.CrossRefPubMed Reinisch W, Gasche C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, Dejaco C, Waldhor T, Bakos S, Vogelsang H, Gangl A, Lochs H. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999; 94:2156–2164.CrossRefPubMed
12.
Zurück zum Zitat Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988; 1084:401–405. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988; 1084:401–405.
13.
Zurück zum Zitat Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341:1437–1439.PubMed Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341:1437–1439.PubMed
14.
Zurück zum Zitat Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119:15–22.PubMed Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119:15–22.PubMed
15.
Zurück zum Zitat Biancone L, Silvestri M, Pallone F. Fecal alpha-1-antitripsin as early indicator of clinical relapse in Crohn's disease: results from 1–4 years' follow up. (abstract) Gastroenterology 1998; 114:3819. Biancone L, Silvestri M, Pallone F. Fecal alpha-1-antitripsin as early indicator of clinical relapse in Crohn's disease: results from 1–4 years' follow up. (abstract) Gastroenterology 1998; 114:3819.
16.
Zurück zum Zitat Arnott IDR, Watts D, Ghosh S. Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther 2002; 16:857–867.CrossRefPubMed Arnott IDR, Watts D, Ghosh S. Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther 2002; 16:857–867.CrossRefPubMed
17.
Zurück zum Zitat Saverymuttu SH, Camilleri M, Rees H, Cavender TP, Hodgson HJF. Indium-111 granulocyte scanning comparison with colonoscopy, histology and fecal indium-111 excretion in assessing disease extent and activity in colitis. Gastroenterology 1986; 90:1121–1128.PubMed Saverymuttu SH, Camilleri M, Rees H, Cavender TP, Hodgson HJF. Indium-111 granulocyte scanning comparison with colonoscopy, histology and fecal indium-111 excretion in assessing disease extent and activity in colitis. Gastroenterology 1986; 90:1121–1128.PubMed
18.
Zurück zum Zitat Saverymuttu SH, Peters AM, Lavender JP, Hodgson HJ, Chadwick VS. 111 Indium autologous leucocytes in inflammatory bowel disease. Gut 1983; 24:293–299.PubMed Saverymuttu SH, Peters AM, Lavender JP, Hodgson HJ, Chadwick VS. 111 Indium autologous leucocytes in inflammatory bowel disease. Gut 1983; 24:293–299.PubMed
19.
Zurück zum Zitat Giaffer MH, Tindale WB, Holdsworth D Value of technetium-99m HMPAO-labelled leucocyte scintigraphy as an initial screening test in patients suspected of having inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8:1195–1200.PubMed Giaffer MH, Tindale WB, Holdsworth D Value of technetium-99m HMPAO-labelled leucocyte scintigraphy as an initial screening test in patients suspected of having inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8:1195–1200.PubMed
20.
Zurück zum Zitat Biancone L, Scopinaro F, Ierardi M, Paoluzi P, Marcheggiano A, Di Paolo MC, Porowska B, Centi Colella A, Pallone F. 99mTc-HMPAO granulocyte scintigraphy in the early detection of postoperative asymptomatic recurrence in Crohn's disease. Dig Dis Sci 1997; 42:1549–1556.PubMed Biancone L, Scopinaro F, Ierardi M, Paoluzi P, Marcheggiano A, Di Paolo MC, Porowska B, Centi Colella A, Pallone F. 99mTc-HMPAO granulocyte scintigraphy in the early detection of postoperative asymptomatic recurrence in Crohn's disease. Dig Dis Sci 1997; 42:1549–1556.PubMed
21.
Zurück zum Zitat Farrar WL, Cleveland JL, Beckner SK, Bonvini E, Evans SW. Biochemical and molecular events associated with interleukin 2 regulation of lymphocyte proliferation. Immunol Rev 1986; 92:49–65.PubMed Farrar WL, Cleveland JL, Beckner SK, Bonvini E, Evans SW. Biochemical and molecular events associated with interleukin 2 regulation of lymphocyte proliferation. Immunol Rev 1986; 92:49–65.PubMed
22.
Zurück zum Zitat Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Groessner B, Lochs H, Raedler A. Tumour necrosis factor alpha and interleukin-1 beta in relapse of Crohn's disease. Lancet 1999; 353:459–461.PubMed Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Groessner B, Lochs H, Raedler A. Tumour necrosis factor alpha and interleukin-1 beta in relapse of Crohn's disease. Lancet 1999; 353:459–461.PubMed
23.
Zurück zum Zitat Signore A, Chianelli M, Annovazzi A, Bonanno E, Spagnoli LG, Pozzilli P, Pallone F, Biancone L. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med 2000; 41:242–249.PubMed Signore A, Chianelli M, Annovazzi A, Bonanno E, Spagnoli LG, Pozzilli P, Pallone F, Biancone L. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med 2000; 41:242–249.PubMed
24.
Zurück zum Zitat Sandborn WJ. Transcending conventional therapies: the role of biologic and other novel therapies. Inflamm Bowel Dis 2001; 7 Suppl 1:S9–16. Sandborn WJ. Transcending conventional therapies: the role of biologic and other novel therapies. Inflamm Bowel Dis 2001; 7 Suppl 1:S9–16.
25.
Zurück zum Zitat Chianelli M, Signore A, Fritzberg AR, Mather SJ. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol 1997; 24:579–586.CrossRefPubMed Chianelli M, Signore A, Fritzberg AR, Mather SJ. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol 1997; 24:579–586.CrossRefPubMed
26.
Zurück zum Zitat Roca M, Martin-Comin J, Becker W, Bernardo-Filho M, Gutfilen B, Moisan A, Peters M, Prats E, Rodrigues M, Sampson C, Signore A, Sinzinger H, Thakur M. A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime. International Society of Radiolabeled Blood Elements (ISORBE). Eur J Nucl Med 1998; 25:797–799.CrossRefPubMed Roca M, Martin-Comin J, Becker W, Bernardo-Filho M, Gutfilen B, Moisan A, Peters M, Prats E, Rodrigues M, Sampson C, Signore A, Sinzinger H, Thakur M. A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime. International Society of Radiolabeled Blood Elements (ISORBE). Eur J Nucl Med 1998; 25:797–799.CrossRefPubMed
27.
Zurück zum Zitat Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F. Immunoregulation in the gut: success and failures in human disease. Gut 2002; 50:III60–III64.PubMed Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F. Immunoregulation in the gut: success and failures in human disease. Gut 2002; 50:III60–III64.PubMed
28.
Zurück zum Zitat Signore A, Chianelli M, Annovazzi A, Rossi M, Maiuri L, Greco M, Ronga G, Britton KE, Picarelli A. Imaging of active lymphocytic infiltration in coeliac disease with 123I-interleukin-2 and its response to diet. Eur J Nucl Med 2000; 27:18–24.PubMed Signore A, Chianelli M, Annovazzi A, Rossi M, Maiuri L, Greco M, Ronga G, Britton KE, Picarelli A. Imaging of active lymphocytic infiltration in coeliac disease with 123I-interleukin-2 and its response to diet. Eur J Nucl Med 2000; 27:18–24.PubMed
29.
Zurück zum Zitat Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98:811–818.PubMed Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98:811–818.PubMed
30.
Zurück zum Zitat Sciarretta G, Furno A, Mazzoni M, Basile C, Malaguti P. Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance. Gut 1993; 34:1364–1369.PubMed Sciarretta G, Furno A, Mazzoni M, Basile C, Malaguti P. Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance. Gut 1993; 34:1364–1369.PubMed
Metadaten
Titel
99mTc-interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease
verfasst von
Alessio Annovazzi
Livia Biancone
Renato Caviglia
Marco Chianelli
Gabriela Capriotti
Stephen J. Mather
Renzo Caprilli
Francesco Pallone
Francesco Scopinaro
Alberto Signore
Publikationsdatum
01.03.2003
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2003
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-002-1069-x

Weitere Artikel der Ausgabe 3/2003

European Journal of Nuclear Medicine and Molecular Imaging 3/2003 Zur Ausgabe